BRIDGEWATER, N.J., Feb. 7, 2023
/PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global
biopharmaceutical company on a mission to transform the lives of
patients with serious and rare diseases, today announced that
management will present in a fireside chat at the virtual SVB
Securities Global Biopharma Conference on Tuesday, February 14, 2023 at 12:00 p.m. ET.
The fireside chat will be webcast live and can be accessed by
visiting the investor relations section of the Company's website
at www.insmed.com. The webcast will be archived for a
period of 30 days following the conclusion of the live event.
About Insmed
Insmed Incorporated is a global biopharmaceutical company on a
mission to transform the lives of patients with serious and rare
diseases. Insmed's first commercial product is a first-in-disease
therapy approved in the United States, Europe,
and Japan to treat a chronic, debilitating lung disease.
The Company is also progressing a robust pipeline of
investigational therapies targeting areas of serious unmet need,
including neutrophil-mediated inflammatory diseases and rare
pulmonary disorders. Insmed is headquartered in Bridgewater,
New Jersey, with a footprint
across Europe and in Japan. For more information,
visit www.insmed.com.
Contact:
Investors:
Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
eleanor.barisser@insmed.com
Media:
Mandy Fahey
Executive Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/insmed-to-present-at-the-svb-securities-global-biopharma-conference-301740029.html
SOURCE Insmed Incorporated